Hikma Pharmaceuticals Share Price (HIK)
| Bid price | 1,843.00 | Open price | 1,770.50 |
|---|---|---|---|
| Ask price | 1,843.50 | Prev close | 1,843.50 |
| High price | 1,854.50 | Spread | 0.03% |
| Low price | 1,763.20 | Volume | 731,777 |
Register now for FREE live Hikma Pharmaceuticals share prices, Hikma Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Hikma Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Hikma Pharmaceuticals (HIK) and other London Stock Exchange equities.
Hikma Pharmaceuticals Share Price Chart
Register now for FREE Hikma Pharmaceuticals share price charts
Hikma Pharmaceuticals Share Price Information
| Name | Hikma Pharmaceuticals | Epic | HIK |
|---|---|---|---|
| Sector | Pharmaceuticals & Biotechnology | ISIN | GB00B0LCW083 |
| Activites | Hikma Pharmaceuticals plc is a multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: 'njectables, Generics and Branded, based primarily in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2016, Hikma achieved revenues of $1,950 million and profit attributable to shareholders of $155 million. | Index | FTSE 250 |
Hikma Pharmaceuticals Key Numbers
| Latest Share Price (p) | 1,843.50 | Net Gearing (%) | 48.20 |
|---|---|---|---|
| Market Capitalisation (£m) | 4,313.60 | Gross Gearing (%) | 54.90 |
| Shares in issue (m) | 241.46 | Debt Ratio | 41.03 |
| P/E Ratio | -5.08 | Debt-to-Equity Ratio | 0.57 |
| Total dividends per share (p) | 34.00 | Assets / Equity Ratio | 2.22 |
| Dividend Yield (%) | 1.26 | Price to book value | 2.82 |
| Dividend cover (x) | 0.00 | ROCE (%) | -28.48 |
| Earning per share (p) | -351.80 | EPS Growth (%) | -629.02 |
| 52 week high / low | 2,089.00 / 814.20 | DPS Growth (%) | 3.03 |
Hikma Pharmaceuticals Director Deals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 30/05/2018 | BUY | Sigurdur Olafsson | CEO | 20,000 |
| 23/05/2018 | BUY | John Castellani | NED | 1,000 |
| 15/05/2018 | TIN | Mazen Darwazah | ED | 20,000 |
| 15/05/2018 | TIN | Said Darwazah | CH | 27,000 |
| 19/03/2018 | TIN | Mazen Darwazah | ED | 38,501 |
Hikma Pharmaceuticals Company News
Hikma launches treatment for seizures in patients suffering from Lennox-Gastaut syndrome
Hikma Pharmaceuticals launched Monday its treatment for seizures in patients suffering from Lennox-Gastaut syndrome. Clobazam Oral Suspension, and Clobazam Tablet, the generic equivalent to Onfi, would be among the first generics available on the market, the company said. According to IQVIA,...
Hikma launches Clobazam
RNS Number : 8882J Hikma Pharmaceuticals Plc 10 December 2018 London, 10 December 2018 - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable) announces that Hikma Pharmaceuticals USA Inc.,...
Total Voting Rights
RNS Number : 2167J Hikma Pharmaceuticals Plc 03 December 2018 Hikma Pharmaceuticals PLC Total Voting Rights and Capital LONDON, 3 December 2018 - In accordance with the UK Financial Conduct Authority's (the " FCA ") DTR 5.6.1, Hikma Pharmaceuticals PLC...
More Hikma Pharmaceuticals Company News >>
Register now for FREE Hikma Pharmaceuticals company news
Hikma Pharmaceuticals Share Price Discussions
Hikma Pharmaceuticals (HIK)
Floated in London last November at 290p (FTSE-250). Company website www.hikma.com Develops, manufactures and markets branded and non-branded generic pharmaceuticals, as well as in-licensed, patented pharmaceuticals Geographic markets: USA, Europe and the Middle East & North Africa...
Register now for FREE Hikma Pharmaceuticals share price discussions